The Open Access version of this book, available at http://www.tandfebooks.com, has been made available under a Creative Commons Attribution-Non Commercial-No Derivatives 3.0 license. An exploration of how global pharmaceutical products are localized - of what happens when they become ‘glocal’ - this book examines the tensions that exist between a global pharmaceutical market and the locally bounded discourses and regulations encountered as markets are created for new drugs in particular contexts. Employing the case study of the emergence, representation and regulation of Viagra in the Swedish market, Glocal Pharma offers analyses of commercial material, medical discourses and legal documents to show how a Swedish, Viagra-consuming subject has been constructed in relation to the drug and how Viagra is imagined in relation to the Swedish man. Engaging with debates about pharmaceuticalization, the authors consider the ways in which new identities are created around drugs, the redefinition of health problems as sites of pharmaceutical treatment and changes in practices of governance to reflect the entrance of pharmaceuticals to the market. With attention to ‘local’ contexts, it reveals elements in the nexus of pharmaceutcalization that are receptive to cultural elements as new products become embedded in local markets. An empirically informed study of the the ways in which the presence of a drug can alter the concept of a disease and its treatment, understandings of who suffers from it and how to cure it - both locally and internationally - this book will appeal to scholars of sociology and science and technology studies with interests in globalization, pharmaceuticals, gender and the sociology of medicine.

Medicines are vital in improving patient health outcomes and pharmaceutical policy is a fundamental component of any health system. However, the global pharmaceutical policy is ever-evolving and data and quality ‘research-based information’ in this field are scarce. This book fills this gap and provides up-to-date empirical information and evidence-based synthesis. It focuses on pertinent key issues in global pharmaceutical policy including medicines safety, generic medicines, pharmaceutical supply chain, medicines financing, access and affordability of medicines, rational use of medicines, pharmacy health services research and access to vaccines and biological products. Featuring policy case studies from varied countries such as Mexico, Russia, China, Kyrgyzstan, and Pakistan, this book comprises a valuable and comprehensive resource for students, funders, policymakers, academics, and researchers interested in this field.

DIVAnthropological study of the globalization of pharmaceuticals and its effects on local cultures, health, and economics./div

The Price of Global Health is the first book of its kind: an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much needed and invaluable resource for anybody interested, involved in or affected by the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs.

In a rapidly growing global economy, where there is a constant emergence of new business models and dynamic changes to the business ecosystem, there is a need for the integration of traditional, new, and hybrid concepts in the complex structure of supply chain management. Within the fast-paced pharmaceutical industry, product strategy, life cycles, and distribution must maintain the highest level of agility. Therefore, organizations need strong supply chain capabilities to profitably compete in the marketplace. Global Supply Chains in the Pharmaceutical Industry provides innovative insights into the efforts needed to build and maintain a strong supply chain network in order to achieve efficient fulfillment of demand, drive outstanding customer value, enhance organizational responsiveness, and build network resiliency. This publication is designed for supply chain managers, policymakers, researchers, academicians, and students, and covers topics centered on economic cycles, sustainable development, and new forces in the global economy.

There is a strong argument that people throughout the world have a right to receive the medicines they need in an appropriate, affordable, and timely way. Global Pharmaceutical Policy describes the laws, policies, and customs relating to the development and provision of medicines, identifies their strengths and weakness, and then proposes global solutions for getting things better. Here is a masterpiece written in a clear and elegant style. Together, Dukes and Abbott have experience and insight that are unrivalled. Joe Collier, Emeritus Professor of Medicines Policy, St George s, University of London, UK Pharmaceuticals play a central role in health care throughout the world. The pharmaceutical industry is beset with difficulties as increasing research and development expenditure yields fewer new treatments. Public and private budgets strain under the weight of high prices and limited access. The world s poor see little effort to address diseases prevalent in less affluent societies, while the world s wealthy are overusing prescription drugs, risking their health and wasting resources. As the global economic crisis exacerbates pressure on health care budgets, a new presidential administration in Washington, DC has committed to broad health care reform. These circumstances form the backdrop for this extraordinarily timely examination of the global system for the development, production, distribution and use of medicines. The authors are acknowledged experts in the fields of pharmaceutical law and policy, with many years experience advising governments, multilateral organizations and policy-makers on issues involving innovation, access and use of medicines. Supported by a team of independent scientists, doctors and lawyers, they take an insightful look at the issues surrounding global regulation of the pharmaceutical sector, and offer pragmatic suggestions for reform. This book will be of interest to government policy-makers, members of industry, healthcare professionals, teachers, students and lawyers in the fields of public health, intellectual property and international trade.

800x600 This new case study shows how an operationally complex global pharmaceutical company based in Hyderabad, India, responds to the challenges of high demand variability and other uncertainties. It reviews operations spanning the entire pharmaceutical supply chain, including development, manufacturing, drug formulation, and packaging; its 20 manufacturing plants throughout India; and export operations to 40+ countries worldwide. Throughout, it focuses on realistic issues and challenges, offering exceptional value to both students and practitioners. Authors: Sourabh Bhattacharya, Surajit Ghosh Dastidar; both from The Institute of Management Technology.

How do we understand health in relation to society? What role do social processes, structures and culture play in shaping our experiences of health and illness? How do we understand medicine and healthcare within a sociological framework? Drawing on international literature and examples, this new edition of Key Concepts in Medical Sociology: · Systematically explains the concepts that have preoccupied medical sociology from its inception, and which have shaped the field as it exists today. · Includes new entries, such as pandemics and epidemics, the environment, intersectionality, pharmaceuticalization, medical tourism and sexuality. · Begins each entry with a definition of the concept then examines its origins, development, strengths and weaknesses, and concludes with suggested further reading for independent learning. Key Concepts in Medical Sociology is essential reading for students in medical sociology as well as those undertaking professional training in health-related disciplines.

The Global Repositioning of Japanese Religions: An Integrated Approach explores how Japanese religions respond to the relativizing effects of globalization, thereby repositioning themselves as global players. Organized around concrete case studies focusing on the engagement of Japanese Buddhism, Shinto, and several new religious movements in areas such as ecology, inter-religious dialogue, and politics, this book shows that the globalization of Japanese religions cannot be explained simply in terms of worldwide institutional expansion. Rather, it is a complex phenomenon conditioned by a set of pervasive factors: changes in consciousness, the perception of affinities and resonances at the systemic and cultural levels, processes of decontextualization, and a wide range of power issues including the re-enactment of cultural chauvinism. The author investigates these dynamics systematically with attention to broader theoretical questions, cross-cultural similarities, the definition of religion and the perils of ethnocentrism, in order to develop his Global Repositioning model, which constitutes an integrated approach to the study of Japanese religions under globalization. An empirically-grounded and theoretically-informed study of the effects of global trends on local religions, this book will appeal to scholars and students with interests in globalization, religious studies, Japanese studies, Hawaii, sociology, anthropology, and ecology.

THE PHARMACEUTICAL INDUSTRY IS BROKEN From the American hedge fund manager who drastically hiked the price of an AIDS pill to the children’s cancer drugs left intentionally to expire in a Spanish warehouse, the signs of this dysfunction are all around. A system built to drive innovation and improve patient care has been distorted to maximise profits. In Sick Money, the investigative journalist who exposed a billion-pound British price-hiking scandal goes inside the global battle over high drug prices. From secret deals to patients forced to turn to the black market, Billy Kenber reveals how medicines have become nothing more than financial assets. He offers a diagnosis of an industry in crisis - and a prescription for how it could be fixed.